What is the significance of the positive Phase 3 results for ZALTRAT?

The positive Phase 3 results are highly significant as they demonstrate the efficacy of ZALTRAT (aflibercept) in treating second-line metastatic colorectal cancer. This is a key step towards potential regulatory approval by health authorities like the FDA, which could lead to the drug's commercial availability and generate substantial revenue for Regeneron.

What is the role of sanofi-aventis in the development of ZALTRAT?

Sanofi-aventis is a key partner in the development and potential commercialization of ZALTRAT. The press release indicates a collaborative effort, suggesting that sanofi-aventis will likely play a role in marketing and distributing the drug upon approval.

What is the next step for ZALTRAT after these Phase 3 results?

Following positive Phase 3 results, the typical next step involves submitting a New Drug Application (NDA) to regulatory bodies such as the U.S. Food and Drug Administration (FDA) for approval. This filing would trigger a review process by the agency.

What is metastatic colorectal cancer and why is second-line treatment important?

Metastatic colorectal cancer refers to colorectal cancer that has spread to other parts of the body. Second-line treatment is administered to patients whose cancer has progressed after initial therapy. Positive results in this setting indicate a valuable treatment option for patients who have limited alternatives, making it a significant market.

REGN 8-K SEC Disclosure

Summary

Regeneron Pharmaceuticals, Inc. (REGN) announced significant positive Phase 3 clinical trial results for ZALTRAT (aflibercept) in patients with second-line metastatic colorectal cancer. These results, detailed in a press release filed with the SEC on April 26, 2011, represent a crucial milestone for the company's oncology pipeline and its collaboration with sanofi-aventis. The positive outcome suggests a potential new treatment option for a significant patient population, which could lead to substantial future revenue streams.

Key Highlights

1Positive Phase 3 trial results for ZALTRAT (aflibercept) in second-line metastatic colorectal cancer.
2The drug, developed in collaboration with sanofi-aventis, demonstrated efficacy in a key patient subgroup.
3These results are a critical step towards potential regulatory approval and commercialization of ZALTRAT.
4The positive data could significantly enhance Regeneron's oncology franchise and future revenue projections.
5The announcement was made via a press release filed as an exhibit to the Form 8-K.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Corporate Update (Apr 26, 2011)

Summary

Key Highlights

Frequently Asked Questions